Study Details

Study ID 9785-CL-0335
Study Title A Multinational, Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC) – ARCHES Identifier NCT02677896
Compound Name MDV3100 / enzalutamide
Medical Indication or Disease Prostate cancer
Study Sponsor Astellas Pharma Global Development, Inc.
Collaborator Medivation LLC, a wholly owned subsidiary of Pfizer Inc.
Study Start Date 09-Mar-2016
Study Completion Date 14-Oct-2018
Clinical Study Result
Select the language
Plain Language Summary
Select the language